New drug duo tested in fight against aggressive breast cancer

NCT ID NCT07359404

ENROLLING_BY_INVITATION Disease control Sponsor: YING FAN Source: ClinicalTrials.gov ↗

Summary

This study is testing whether combining two existing drugs, sacituzumab govitecan and bevacizumab, can help control advanced triple-negative breast cancer that has spread. It is for people whose cancer has worsened after at least one prior treatment. The main goals are to see if the combination can slow cancer growth and is safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

Conditions

Explore the condition pages connected to this study.